Evaxion Biotech (EVAX) Registration Filing summary

Company overview and business model

• Clinical-stage TechBio company leveraging proprietary AI-Immunology™ platform to develop novel vaccines for cancer, bacterial, and viral infections.

• Demonstrated correlation between AI predictions and clinical response in metastatic melanoma.

• Focus on partnerships, highlighted by an expanded collaboration with MSD.

• Incorporated in Denmark, converted to public limited liability company in 2019.

Financial performance and metrics

• Stockholders' equity was $(4,729,000) as of December 31, 2023, below Nasdaq's $2.5 million requirement.

• Nasdaq granted an extension to regain compliance, and as of February 2025, the company is fully compliant and remains listed.

• Aggregate market value of public float as of March 13, 2025, was approximately $28.995 million.

• $5,184,174 in securities sold in the prior 12 months under Form F-3.

Use of proceeds and capital allocation

• Net proceeds intended for working capital and general corporate purposes, with significant discretion in allocation.